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Review of Research Methods 
Diagnostic Test Accuracy Research in Older Adults  
 
  
2 
 
Abstract: Diagnostic test accuracy (DTA) describes a field of research that aims to assess how well a 
test is able to detect or exclude a condition of interest.  Although geriatric medicine is not as reliant 
on investigations as other medical disciplines, almost all patient encounters with older adults will 
involve some form of diagnostic assessment.  Thus, understanding the terminology and methods of 
DTA is essential for any clinician.  In this review we use examples based around the diagnosis of 
dementia to highlight issues in DTA research.  Some of these are generic to any DTA research and 
some are particularly pertinent to older adults.  One can apply a test accuracy framework to a 
clinical question by defining four key components: the condition of interest; the index test(s) (i.e. the 
assessment(s) of interest); the reference standard (the best available method for assessing the 
condition of interest) and the population or healthcare setting in which testing takes place.  Test 
accuracy is often described using complementary measures of sensitivity and specificity.  However, 
many other metrics to describe test accuracy are available; in clinical practice predictive values may 
have greater utility.  These and other descriptive statistics can be derived from a two by two table 
that cross-classifies the index test results with the reference standard results.  Test performance and 
utility is not only determined by accuracy, other measures such as feasibility and acceptability should 
be considered and may be of particular importance when describing test performance in older 
adults with physical and cognitive impairments.     
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Is test accuracy relevant to older adult practice? 
With so many research methods available to the older adult researcher, many of which have been 
reviewed in this Age and Ageing series [1,2], test accuracy research may not seem the most 
obviously relevant to our patient group.  As a speciality, Geriatric Medicine prides itself on not being 
overly reliant on sophisticated imaging or laboratory tests.  However, if we consider our clinical 
encounters we can see that concepts such as screening and diagnosis are central to geriatric 
practice.  The resulting questions can be understood using a test accuracy research framework and 
so, by implication, an understanding of test accuracy research should be considered ‘core 
business.(Figure 1)   
The ‘testing of tests’ should not be the exclusive reserve of interested academics.  Recent 
developments in imaging and ‘omics-based technologies have resulted in an increasing clinical 
diagnostic toolkit.  These new technologies offer exciting opportunities, but we should not assume 
that a new test is necessarily a better test.  We must exercise the same rigour with test accuracy 
research as we would with a trial of a new treatment or device.  The same argument holds for 
existing and established tests; it is sobering to see how many tests have become embedded within 
practice with little or no supporting test accuracy evidence. 
The methodology that underpins test accuracy research is constantly evolving in-line with the 
developments in diagnostics and technology.  In this review we will provide an introduction to the 
field with particular reference to the application of classical test accuracy in studies of older adults.  
For the reader wishing a more detailed discussion of the science and methodology of test accuracy, 
we have included key papers and a textbook as references.[3-6]  The textbook addresses specific 
issues in dementia diagnostic test accuracy and performance of cognitive screening tests.[3] 
 
Language of test accuracy research  
Studies of diagnostic test accuracy (DTA) describe how well a test(s) correctly identifies or excludes a 
condition of interest (i.e. target condition).  Test accuracy is only one phase in the multifaceted 
evaluation of a clinical test.  The early phase of the process focusses on properties such as test 
reliability, precision, responsiveness and, following assessment of DTA, a later phase addresses the 
utility of the test in informing clinical decisions and ultimately improving patient outcomes.(Figure 2)  
Several authors have developed frameworks for the process of test evaluation, sometimes designed 
for specific test types such as laboratory tests [7] genetic tests [8], biomarkers [9] and imaging 
tests.[10]  
Test performance depends on various factors such as characteristics of the test and its conduct 
(including expertise of assessors), purpose (e.g. diagnosis, screening, staging, disease surveillance, 
etc.), population and definition of the target condition.[11] Therefore, a clear definition of the 
intended use and role of a test for a specific population within the context of a clinical pathway is 
essential. Test accuracy is best understood by applying a framework that defines four key 
components: the target condition, population, index test(s), and reference standard.  We will 
address each in turn and use the example of diagnosis of dementia to illustrate some of the 
challenges of DTA research in older adults.  
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Target condition: The target condition is the condition or clinical state that you wish to diagnose, 
exclude or differentiate.  In some situations the target condition is obvious, for example using 
electrocardiograph or cardiac enzymes to diagnose cardiac ischaemia.  However, the target 
condition should not be assumed and a clear, operationalised definition is mandatory.  For example, 
in a chronic progressive syndrome such as dementia, we must be clear as to which form of dementia 
and which stage of the condition we are looking to diagnose.  A test designed to assess for mild 
cognitive impairment (MCI) may have very different test properties if used to assess for frank 
dementia.  Thus, we should be cautious of extrapolating DTA results from a narrow to a broader 
target condition.  The popular Montreal Cognitive Assessment (MoCA) was designed and validated 
for MCI[12] but has now entered practice as a screen for dementia.   Consequently the accuracy of 
MoCA as a dementia assessment differs from that reported in the original papers describing the 
test.[13]   
 
Population: Measures of test accuracy are not usually transferable across different populations and 
settings due to changes in disease spectrum.[14]  The spectrum of disease in a population will 
depend on prevalence, disease severity, clinical setting and prior testing.  For example, a brief 
cognitive screening test will perform differently (and will have different preferred properties) when 
used in a specialist memory clinic compared to when used in a general practice consultation.  In 
dementia DTA research, a particular issue is around the case-mix of the population and the potential 
severity of any cognitive syndrome.  In a secondary care service, disease is likely to be advanced and 
differentiating those with and without disease may be relatively straightforward.  If a test validated 
in secondary care is then used in primary care, where the proportion with disease is lower and 
disease is less advanced, test accuracy may differ considerably.   
 
Index test: The index test describes the assessment(s) or tool(s) of interest.  Index tests range from 
history taking and clinical symptoms to state of the art imaging and genomics.  The index test may be 
more accurate, quicker, cheaper or less burdensome than the usual optimal test.  If this is not the 
case one has to ask why the new test is required. 
To enable analysis of test accuracy, the index test result is interpreted as positive or negative.  As 
many biological states exist on a continuum, tests often give a range of values or scores.  In this 
situation we have to define a threshold (cut-point) that categorises the index test result into positive 
and negative.  Again, if we consider the MoCA, a range of scores are possible and a cut-point is used 
to determine ‘test positive’ and ‘test negative’ individuals.[13]  While this dichotomisation is 
necessary for DTA analysis and allows ease of interpretation, important granularity can be missed.  
With a cognitive test it may be more useful to consider performance in each of the differing domains 
of memory, visuospatial, executive function tested rather than an aggregate score.  Newer cognitive 
tests such as the Oxford Cognitive Screen actively discourage a reductionist pass/fail approach.[15]       
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Reference standard: The reference standard is the best available test for verifying the presence or 
absence of the target condition.  This may be a single test or a combination of several tests and 
clinical information.  Therefore, the description ‘gold standard’ is not always appropriate, as the 
reference standard may not be the optimal diagnostic approach.  In dementia research many would 
consider the gold standard to be detailed neuropathology but clearly in large scale assessment of a 
cognitive screening test one could not expect every patient to offer neuropathological materials.  
In practice, the reference standard is often expert clinical diagnosis but the synthesis of information 
and gestalt that informs clinical diagnosis has inherent limitations that need to be borne in mind 
when interpreting test accuracy.  Even in expert hands, the diagnosis of dementia has a degree of 
inter-observer variability.  If one then considers the differing classification systems available to 
diagnose dementia and dementia subtypes, the potential variation becomes even more pronounced. 
 
Design of test accuracy studies  
The usual design of a DTA study is cross-sectional. Participants representative of those in whom the 
test will be applied in practice are recruited sequentially or randomly, and all participants get the 
same index test and reference standard.  For a new test, a case-control design is often used, i.e., the 
test is assessed using one group of participants known to have the target condition and another 
group without the target condition (two-gate design).[16]  This design is a useful first step but is 
rarely the ‘final word’ on accuracy because such designs tend to inflate test accuracy by including 
phenotypic extremes.[16]  Ideally, promising results from a case-control DTA study should be 
followed by a prospective study of participants suspected of having the condition.  If the target 
condition is rare, researchers sometimes ‘enrich’ a population with additional cases.  For example, a 
test designed to specifically look for the frontotemporal form of dementia may include all referrals 
to a memory clinic and additional cases already diagnosed.   
Most published DTA studies assess the accuracy of a single index test.  This is often not the clinical 
question of greatest relevance.  For many conditions, particularly dementia assessment, there is 
more than one potential index test and the clinician will want to know which test is more accurate 
for a certain population.  For example, how does MoCA compare with Folstein’s Mini-Mental State 
Examination (MMSE)[17] for detecting MCI in community-dwelling older adults?  Ideally, the 
relevant index tests should be compared ‘head-to-head’ in the same study population.  This can be 
achieved by performing all the index tests on each participant (paired or within-subject design), or 
by randomising participants to a particular index test.[18,19] In both designs, all participants get the 
reference standard.  Depending on the nature of the tests, the paired design may increase the 
burden of testing and so may not be ethically feasible, while the randomised design potentially 
requires a larger sample size. 
 
Quantifying test accuracy  
Ideally, an index test should discriminate perfectly between those with and those without the target 
condition, i.e. no false negative or false positive test errors.  In clinical practice, this is rare.  By cross-
classifying index test and reference standard results, we create a two by two table of the number of 
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true positives, false positives, true negatives and false negatives.  Various metrics for quantifying test 
accuracy can be computed using the data in this table.(Figure 3)  When reporting test accuracy it is 
good practice to present the table or give sufficient information to allow the reader to reconstruct 
the table.   
 
Sensitivity, specificity, and threshold effect: Sensitivity and specificity are the most commonly used 
test accuracy measures.[20]  Sensitivity, also known as the true positive rate, is the proportion of 
those with the target condition that are correctly identified by the index test as ‘cases’.  Specificity, 
also known as the true negative rate, is defined as the proportion of those without the target 
condition that are correctly identified by the test as ‘non-cases’.   
There is a negative correlation between sensitivity and specificity induced by varying test threshold.  
Consider MMSE for assessment of dementia where the traditional cut-off is 24.  If we use a higher 
cut-point, we will detect more people with dementia (higher sensitivity) but at the expense of 
labelling more people without dementia as having the condition (lower specificity).  The receiver 
operating characteristic (ROC) plot is a graphical illustration of this trade-off between sensitivity and 
specificity.(Figure 4)  Traditionally, sensitivity is plotted against 1-specificity for a range of thresholds.  
The position of the resulting ROC curve indicates the accuracy of the test; the higher the accuracy of 
the test, the closer the curve is to the upper left hand corner of the plot where sensitivity and 
specificity are both 100%.  The area under the ROC curve (AUC) is often used as a global measure of 
test accuracy, with higher values signifying greater test accuracy.  As the AUC is a single measure, 
when used in isolation its clinical utility is limited because it does not provide any information on 
how patients are misclassified (i.e. numbers of false positive and negative).  The ROC plot can be 
used to compare the accuracy of different tests within a study. 
 
Positive and negative predictive values: In clinical practice our interest is usually whether the test 
result helps classify the patient.  The positive predictive value (PPV) is the proportion of those with 
positive test results who truly have the disease while the negative predictive value (NPV) is the 
proportion of those with negative test results who truly do not have the disease.  As stated earlier, 
test performance is susceptible to disease spectrum, but predictive values in particular are directly 
affected by prevalence.  Therefore, assessment of predictive values is inappropriate for case-control 
studies and enriched samples because prevalence in the sample is artificial.  
 
Applying test accuracy in practice 
For the clinician faced with a variety of differing test strategies[21], a common question is ‘what 
values of sensitivity and specificity would suggest a good test’.  There is no correct answer as the 
preferred trade-off between sensitivity and specificity is dependent on context.  One must consider 
the purpose of testing and the implications of a false positive and false negative result.  We can 
illustrate this point with a topical example.  There has been considerable recent interest in CSF based 
dementia biomarkers.  Abnormal levels of amyloid or tau proteins are associated with future risk of 
Alzheimer’s disease dementia.  However, when CSF biomarker properties are described using two by 
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two table based metrics, sensitivity and specificity of the biomarkers for diagnosis of 
undifferentiated dementia are not perfect.  The implications of this are worth considering.  If the 
test gives a false negative result in a middle aged person with early stage Alzheimer’s disease, then 
the person will be misdiagnosed as normal.  With no curative treatment for preclinical (or clinical) 
dementia this mislabelling has limited clinical implications and the disease will eventually be 
diagnosed when symptoms become apparent.  However, consider another person without dementia 
who receives a false positive result.  They will be misdiagnosed as having a progressive 
neurodegenerative condition with likely substantial negative effects on psychological health and 
implications for insurance, employment etc.  Thus, one could argue that for the dementia screening 
scenario we would want the test to be highly specific and would accept a poorer sensitivity. 
For a new test, the question may be ‘what is the added value of the new test beyond what is already 
known from previous tests?’  For example, in a study looking at CSF dementia biomarkers, the 
authors found reasonable test accuracy of these biomarkers, but when considered in the context of 
standard memory testing, there was little additional value of the novel, expensive invasive tests.[23]  
Quantifying the added value of a new test over an existing test paradigm is complex and, as alluded 
to in the preceding section, needs to consider the relative consequences of changes in true positive 
and true negative rates.[22]  
 
Moving beyond sensitivity and specificity 
Test accuracy is only part of the clinical evaluation process.  The clinical value of a test depends on 
whether the information provided leads to improved patient outcomes.[24]  Accuracy is not 
synonymous with clinical effectiveness and there are many plausible reasons why a new test with 
greater accuracy may not result in improved patient outcomes.  The framework by Ferrante di 
Ruffano et al describes the mechanisms that commonly affect health outcomes including feasibility, 
acceptability, interpretability of test results and clinician confidence in the test.[25]  Thus, once 
potentially favourable test accuracy is demonstrated this should be followed by ‘real world’ 
assessments that describe the test-treatment-outcomes pathway.  Ultimately, the most important 
measure is whether the use of the test improves clinical outcomes (clinical utility studies). The test-
treatment randomised controlled trial (RCT) is regarded as the ideal study design for evaluating 
clinical utility. In such RCTs, patients are randomised between new and existing tests, followed by 
appropriate management or intervention based on test results, and finally patient outcomes are 
measured and assessed.  However, the cost and duration of these RCTs often make them 
unrealistic.[24]  
In the context of testing in the older adult, test accuracy needs to be considered alongside other 
properties including feasibility and acceptability.  Greater test accuracy may come at the cost of 
increased test administration time, more invasive testing and greater test burden for both the 
patient and the assessor.  An accurate test that can only be completed by a small proportion of the 
intended population has limited value.  This is an issue for all healthcare settings but is likely to be 
particularly pertinent when assessing frail older adults.  To continue our theme of dementia 
assessment, we can consider multi-domain neuropsychological testing (neuropsychological battery 
[NPB]).  In many dementia texts, NPB is considered the ideal assessment strategy, in fact some 
studies use NPB as the ‘gold standard’ for diagnosing dementia.  However, the lengthy, detailed 
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testing required may not be tolerated and this non-completion is likely to be over-represented in 
those with underlying cognitive problems.  The potential bias caused by this partial verification 
should not be under estimated and the way missing values of index test and reference standard are 
handled in DTA analysis can lead to very different estimates of test accuracy.[26]  Some authors have 
argued that the classical two by two table should be supplemented by additional cells describing the 
numbers who are ‘untestable’.     
  
Assessing reporting and methodological quality 
As this brief review has highlighted, test accuracy research is challenging.  Deficiencies in reporting 
have been recognised as a particular problem for DTA research.  In response, the Standards for 
Reporting Diagnostic Accuracy (STARD) working group created best practice guidance.[4]  There is 
evidence that reporting standards for DTA research are now improving [27] and this is at least in part 
driven by journals (including Age and Ageing) mandating that authors of DTA research follow STARD 
guidance.  Test accuracy is a fast moving field and an update of STARD guidance was published in 
2015, along with guidance on DTA reporting in abstracts and specific DTA guidance for dementia.[28]  
Comprehensive, transparent reporting will not save a methodologically flawed study and as well as 
reporting, guidance around the design and conduct of DTA research is also useful.  The Quality 
Assessment of Diagnostic Accuracy Studies tool (QUADAS) and more recently the updated QUADAS-
2 tool offers a framework for assessing DTA studies in terms of patient selection, index test, 
reference standard, and participant flow and timing of assessments.[6]  A more detailed discussion 
of QUADAS is available in an earlier Age and Ageing review.[2]  STARD and QUADAS-2 can guide 
critical appraisal of DTA work and so have particular value in systematic review and meta-analysis of 
DTA.[29,30]  However, even if not considering formal systematic synthesis of DTA research, we 
would encourage anyone considering running, peer-reviewing or simply reading the report of a test 
accuracy study to make use of QUADAS-2 and STARD resources.  
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Figure 1. Diagnostic test accuracy in geriatric medicine. 
A&E, accident and emergency; CSF, cerebrospinal fluid; CT, computed tomography; DSM 5, 
diagnostic and statistical manual of mental disorders fifth edition; ICD10, international classification 
of diseases tenth revision; MRI, magnetic resonance imaging. 
The cartoon illustrates how clinical questions can be formatted as hypotheses suitable for diagnostic 
test accuracy research. 
 
  
Is the 4 ‘A’s test 
for delirium 
any good in 
A&E?
I think this man 
has dementia, will 
I order an MRI           
or CT scan? 
Do CSF amyloid 
levels REALLY tell 
me anything about 
Alzheimer’s?
Index: 4 ‘A’s test 
Reference:  DSM 5 diagnosis of delirium 
Condition:  Delirium 
Setting:  Accident &  emergency departments 
Q:  What is the accuracy of the 4 ‘A’s test as a 
delirium screen in accident and emergency?
Index: MRI brain and CT brain 
Reference:  ICD 10 clinical diagnosis 
Condition:  All cause dementia
Setting:  Geriatric assessment unit  
Q:  What is the comparative accuracy of CT 
and MRI based neuroimaging for diagnosis of 
dementia in an older adult hospital setting?
Index: CSF beta-amyloid
Reference:  ICD 10 clinical diagnosis 
Condition:  Alzheimer’s  disease dementia
Setting:  Memory clinic  
Q:  What is the accuracy of CSF beta-amyloid 
for diagnosis of Alzheimer’s disease dementia 
in a specialist outpatient setting?
12 
 
 
 
 
Figure 2. Potential phases of test development and assessment. 
MRI, magnetic resonance imaging; ROC, receiver operating characteristic. 
 
  
Technical 
development 
Clinical 
validity
Clinical    
utility
Laboratory optimisation of a new biomarker assay 
Inter-scanner variability of a quantitative brain MRI sequence 
Psychometrics & norming of a cognitive screening test
(correlations, reliability, internal consistency,  responsiveness) 
Can the biomarker distinguish dementia cases from controls 
Can the MRI results predict progression from MCI to dementia
Can the screening test exclude those with normal  cognition
(sensitivity/specificity, predictive values, ROC curves) 
Can the biomarker select those most likely to respond to treatment 
What is the added value of brain MRI over usual imaging
Does the screening test effectively prioritise referral to a memory clinic
(reclassification,  decision trees, health economics) 
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Reference 
standard present 
(dementia, ICD-10 
criteria) 
Reference 
standard absent 
(dementia, ICD-10 
criteria) 
 
Index test (eg MMSE) 
positive 
True positives 
(A) 
False positives  
(B) 
PPV 
A ÷ (A + B) 
Index test (eg MMSE) 
negative 
False negatives  
(C) 
True negatives  
(D) 
NPV 
D ÷ (C + D) 
 
Sensitivity 
A ÷ (A + C) 
Specificity 
D ÷ (B + D) 
 
Other paired measures of accuracy: 
Positive likelihood ratio (LR+):      sensitivity ÷ (1 – specificity) 
Negative likelihood ratio (LR-):     (1 – sensitivity) ÷  specificity 
 
False alarm rate:                             1 - PPV 
False reassurance rate:                  1 - NPV 
Single measures of accuracy 
Diagnostic odds ratio (DOR):        (A x D) ÷ (B x C) 
Youden index:                                 sensitivity + specificity – 1 
Overall accuracy:                            (A + D) ÷ (A + B + C + D) 
 
Figure 3. The classical two by two test accuracy table and metrics that can be derived from this 
table.  
MMSE, Mini-Mental State Examination. 
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Figure 4. Receiver operating characteristic curve of Mini-Mental State Examination for detecting 
dementia 
The numbers within the figure indicate the cut-off score for each pair of sensitivity and specificity. 
Figure authors’ own with data based on [17] 
 
